CHAPEL HILL, N.C., May 26, 2017 /PRNewswire/ -- Scientific publications remain the principal way that biopharmaceutical organizations
With growing calls for transparency and data disclosure, global publications leaders find themselves in a balancing act—ensuring both scientific credibility and commercial viability. To help publications leaders navigate this emerging landscape, research and consulting leader Best Practices, LLC undertook benchmarking research to investigate how top pharmaceutical and biotechnology companies shape their global scientific publication strategies to maintain credibility in the scientific community and deliver publications that drive brand success.
The study found that open access platforms are gaining popularity for publication processes; 44% of companies in the study believe such platforms will impact publication strategy going forward. Part of the allure for open access platforms is they make information readily available to physicians and patients alike. In the wake of open access platforms, companies foresee an impact on areas such as journal selection, publication approval and delivery, and speed of data disclosure.
In particular, this study provides benchmarks around publications structure and leadership; staffing and budget levels; publication strategy creation and data delivery; publication channel utilization across product lifecycle; and measuring publication effectiveness. In addition, the 85-page study identifies publication strategy changes for the new marketplace, best practices for maximizing the effectiveness of strategic publication planning, top publication challenges and lessons learned for implementing successful scientific publication strategy.
"Best Practices in Scientific Publications Strategy: Managing Reputation, Clinical Trial Results and Commercial Relevance" will help publication leaders better understand how an effective publications strategy can boost an organization's scientific credibility and a new product's commercial viability.
Key topics in the study include:
For this study, Best Practices, LLC engaged 20 leaders from 19 biopharmaceutical companies through a benchmarking survey and executive interviews.
To access the full report or to download a complimentary summary containing insights found in this report, click on the following link: http://www.best-in-class.com/rr1449.htm.
For related research, visit the Best Practices, LLC Web site at www.best-in-class.com/.
ABOUT BEST PRACTICES, LLC Best Practices, LLC is a leading benchmarking, consulting and advisory services firm serving biopharmaceutical and medical device companies worldwide. Best Practices, LLC's clients include all the top 10 and 48 of the top 50 global healthcare companies. The firm conducts primary research and consulting using its comprehensive proprietary benchmarking tools and analysis.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/using-scientific-publications-strategy-to-ensure-a-pharmaceutical-companys-credibility-and-a-products-viability-300464706.html
SOURCE Best Practices, LLC
Subscribe to our Free Newsletters!
PUVA or photochemotherapy is used to treat several skin disorders with the help of UV light and the ...
Breathing in unclean air due to increasing air pollution could cause kidney damage with resultant ...
Benign prostatic hyperplasia or enlarged prostate is a noncancerous condition observed in men above ...View All